News
Selected for "China ESG Listed Companies Pioneer 100" for Three Consecutive Years, Sino Biopharm's ESG Practices Continue to Gain Authoritative Recognition
Release Date: 2025-11-07
Recently, the ESG China · Innovation Annual Conference (2025) and the first ESG International Expo were held in Beijing. At the conference, China Media Group, together with the State-owned Assets Supervision and Administration Commission of the State Council (SASAC), the All-China Federation of Industry and Commerce (ACFIC), the National Economic Research Think Tank of the Chinese Academy of Social Sciences (CASS), and the China Enterprise Reform and Development Society (CERDS), jointly released the "China ESG Listed Companies Pioneer 100" list. Sino Biopharm (1177.HK) was selected for the third consecutive year for its outstanding performance in the Environmental, Social, and Governance (ESG) field.
![]()
The 2025 list was based on a sample of 6,508 Chinese listed companies on the A-share and Hong Kong stock markets as of April 30, 2025. The selection was conducted based on an ESG evaluation system of 122 indicators that are aligned with international standards and adapted to national conditions. A comprehensive screening was then performed based on factors such as corporate ESG activity and influence, ultimately selecting 100 ESG pioneer companies that represent the highest level of ESG performance among Chinese listed companies.
Being selected for the "China ESG Listed Companies Pioneer 100" for the third consecutive year is one of the important achievements marking the successful conclusion of Sino Biopharm's first "ESG Three-Year Plan (2022-2024)". It also signifies that Sino Biopharm's comprehensive performance in areas such as ESG governance structure, environmental management, social responsibility fulfillment, and information disclosure transparency is among the forefront of domestic listed companies.
In the future, guided by its second "ESG Three-Year Plan (2025-2027)", Sino Biopharm will continue to make progress in specialized governance areas such as ESG risk management, carbon neutrality actions, and sustainable procurement. It will systematically enhance the group's overall ESG practice level, promote the fuller and deeper integration of ESG management into the entire process of corporate decision-making and business operations, and steadily advance towards becoming an industry benchmark in ESG management.
- Previous:Keeping the "CIIE Appointment", Sino Biopharm Joins Hands with Global Partners to Deepen Pharmaceutical Innovation Cooperation
- Next:Ms. Theresa Tse Invited to Attend 2025 International Biomedical Industry Innovation Conference Beijing Forum,Sino Biopharm's Frontier Technology Innovation R&D Center to be Established in International Pharmaceutical Innovation Park
